Valuation: Changchun BCHT Biotechnology Co.

Capitalization	8.33B 1.2B 1.03B 960M 893M 1.66B 108B 1.79B 11.04B 4.35B 51.75B 4.48B 4.39B 189B	P/E ratio 2025 *	10.7x	P/E ratio 2026 *	7.02x
Enterprise value	8.33B 1.2B 1.03B 960M 893M 1.66B 108B 1.79B 11.04B 4.35B 51.75B 4.48B 4.39B 189B	EV / Sales 2025 *	-	EV / Sales 2026 *	-
Free-Float	22.45%	Yield 2025 *	0.94%	Yield 2026 *	-

More valuation ratios * Estimated data

Chart: Changchun BCHT Biotechnology Co.

Timeframe

Style

Dynamic Chart

Latest news: Changchun BCHT Biotechnology Co.

11-13	BCHT Biotechnology Gets Nod to Trial Vaccines Against Pertussis, Diphtheria, Tetanus	MT
25-10-30	Changchun BCHT Biotechnology Co. Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
25-10-09	Changchun High-Tech Unit Gets Approval for Combo Vaccine Trials; Shares Up 5%	MT
25-08-29	Changchun BCHT Biotechnology Co. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25-06-19	Changchun BCHT Biotechnology Co.(SHSE:688276) dropped from Shanghai Stock Exchange Health Care Sector Index	CI
25-04-20	Changchun BCHT Biotechnology Co. announces Annual dividend, payable on June 18, 2025	CI
25-04-20	Changchun BCHT Biotechnology Co. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
25-04-20	Changchun BCHT Biotechnology Co. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
25-02-18	Changchun BCHT Biotechnology Deputy General Manager Quits	MT
25-01-29	BCHT Biotechnology to Acquire 33% of Chuanxin Biopharma	MT
24-10-25	Changchun BCHT Biotechnology Co. Reports Earnings Results for the Nine Months Ended September 30, 2024	CI
24-08-16	Changchun BCHT Biotechnology H1 Profit Up 24%, Operating Income Rises 11%	MT
24-08-08	Changchun BCHT Biotechnology Co. Reports Earnings Results for the Half Year Ended June 30, 2024	CI

More news

Managers and Directors: Changchun BCHT Biotechnology Co.

Manager	Title	Age	Since
Wei Kong CEO	Chief Executive Officer	61	2003-12-31
Zhao Feng Meng DFI	Director of Finance/CFO	62	2019-01-31
Chang Lin Zhu CTO	Chief Tech/Sci/R&D Officer	58	2003-12-31

Director	Title	Age	Since
Xiu Feng Li BRD	Director/Board Member	57	2004-02-29
Xing Gong Zhu BRD	Director/Board Member	59	2021-08-02
De Shen Zhang BRD	Director/Board Member	62	2019-02-20

More insiders

Specialty & Advanced Pharmaceuticals

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-0.30%	-0.84%	-12.93%	-71.16%	1.2B
MERCK KGAA	+0.85%	+1.33%	-8.03%	-34.01%	65.56B
KYOWA KIRIN CO., LTD.	+0.27%	-0.16%	+12.34%	-9.58%	8.5B
HALOZYME THERAPEUTICS, INC.	-0.85%	-1.74%	+29.95%	+39.57%	8.37B
SK BIOPHARMACEUTICALS CO., LTD.	+0.67%	-3.76%	+9.75%	+66.99%	6.4B
YUHAN CORPORATION	-0.28%	-4.77%	-19.48%	+113.36%	5.47B
INDIVIOR PLC	-1.05%	-8.18%	+179.31%	+37.88%	4.06B
BETTA PHARMACEUTICALS CO., LTD.	-0.70%	-2.10%	-10.96%	-20.57%	3.01B
SUPERNUS PHARMACEUTICALS, INC.	-0.52%	-2.17%	+32.49%	+24.75%	2.87B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+1.89%	+3.79%	+56.78%	+41.82%	2.77B
Average	-0.00%	-1.40%	+26.92%	+18.91%	10.82B
Weighted average by Cap.	+0.47%	+0.07%	+6.61%	-6.82%

See all sector performances

Changchun BCHT Biotechnology Co is a China-based innovative biomedical company mainly dedicated to the prevention and treatment of infectious diseases. The Company is mainly engaged in the research and development, production and sales of human vaccines. The Company has three approved vaccine products: varicella vaccine, rabies vaccine and freeze-dried nasal spray flu vaccine. The Company also has other vaccines under development and fully human monoclonal antibody under development for the prevention and control of infectious diseases. The Company mainly conducts business within the domestic market.

Employees

1,274

Sector

Pharmaceuticals

Calendar

03-11 - Q4 2025 Earnings Release

More about the company

Quotes

Date	Price	Change	Volume
26-01-16	20.14 ¥	-0.30%	3,035,051
26-01-15	20.20 ¥	-0.69%	2,929,193
26-01-14	20.34 ¥	-0.73%	4,928,716
26-01-13	20.49 ¥	+0.24%	4,760,139
26-01-12	20.44 ¥	+0.64%	3,913,989

End-of-day quote Shanghai S.E., January 15, 2026

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

20.14CNY

Average target price

32.00CNY

Spread / Average Target

+58.89%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

End-of-day quote Shanghai S.E. Other stock markets 2026-01-16			5-day change	1st Jan Change
20.14 ^CNY	-0.30%		-0.84%	+6.79%

1 day	-0.30%
1 week	-0.84%
Current month	+6.79%
1 month	+5.17%
3 months	-8.12%
6 months	-9.44%
Current year	+6.79%

1 week	19.98	20.9
1 month	18.83	20.9
Current year	18.85	20.9
1 year	18.83	26.3
3 years	18.83	74.99
5 years	18.83	135.88
10 years	18.83	135.88

	2025 *	2026 *
Net sales	-	-
Net income	780M 112M 96.55M 89.88M 83.67M 156M 10.16B 168M 1.03B 408M 4.85B 420M 411M 17.7B	1.19B 170M 147M 137M 127M 237M 15.44B 255M 1.57B 619M 7.36B 638M 625M 26.89B
Net Debt	-	-

Changchun BCHT Biotechnology Co. Stock

Equities

688276

CNE100005XY6